Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $55.8 million.

  • Phathom Pharmaceuticals' Receivables - Net rose 16500.57% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 16500.57%. This contributed to the annual value of $38.8 million for FY2024, which is 227000.61% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Receivables - Net stood at $55.8 million, which was up 16500.57% from $51.3 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Receivables - Net registered a high of $55.8 million during Q3 2025, and its lowest value of $1.6 million during Q4 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Receivables - Net value was $28.7 million (recorded in 2024), while the average stood at $27.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 227000.61% in 2024, then soared by 16500.57% in 2025.
  • Quarter analysis of 3 years shows Phathom Pharmaceuticals' Receivables - Net stood at $1.6 million in 2023, then surged by 2270.01% to $38.8 million in 2024, then soared by 43.8% to $55.8 million in 2025.
  • Its Receivables - Net stands at $55.8 million for Q3 2025, versus $51.3 million for Q2 2025 and $36.4 million for Q1 2025.